Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKD-828 + D097 + D337
- Development stage
- Unknown
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CKD-828 + D097 + D337 appears to refer to a combination therapy, with CKD-828 being a fixed-dose combination of S-amlodipine (an active isomer of amlodipine, a calcium channel blocker) and telmisartan (a long-acting angiotensin II receptor blocker), both of which are antihypertensive agents. CKD-828 has been shown to provide superior blood pressure-lowering efficacy compared to S-amlodipine monotherapy, with favorable safety outcomes, in patients with hypertension inadequately controlled on S-amlodipine. D097 and D337 do not correspond to recognized drug substances or products in public pharmaceutical sources, suggesting they may be investigational code names, study arms, components not yet publicly characterized, or errors. Therefore, the combination as stated cannot be fully described beyond the well-characterized component CKD-828[3][5].
- Other names
- CKD-828 + D097 + D337
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on CKD-828 + D097 + D337.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKD-828 + D097 + D337.